Certolizumab pegol

Essential medicine status

General description

INN	Certolizumab pegol
Medicine type	Biological agent
EML status history	First added in 2023 (TRS 1049) for Rheumatoid arthritis Changed in 2023 (TRS 1049) for Axial spondyloarthritis Changed in 2023 (TRS 1049) for Juvenile idiopathic arthritis Changed in 2023 (TRS 1049) for Crohn disease site Added in 2025 (TRS 1064) for Psoriasis of unspecified type
Therapeutic equivalent for	adalimumab for Axial spondyloarthritis, unspecified adalimumab for Crohn disease, unspecified site adalimumab for Juvenile idiopathic arthritis, unspecified adalimumab for Rheumatoid arthritis adalimumab for Psoriasis of unspecified type
Wikipedia	Certolizumab pegol
DrugBank	Certolizumab pegol